Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.113
Sang Hee Park, Y. Zhong, A. Sima, V. Patel, J. Zhuo, C. Roberts-Toler, B. Becker, S. Hovland, B. Strober
Introduction: Better understanding of the relationship between quality of life and treatment patterns in psoriasis may help guide therapeutic algorithms. This study evaluated the association between patient-reported disease burden and treatment switching from nonbiologic to biologic therapy in patients with plaque psoriasis enrolled in the CorEvitas Psoriasis Registry. Methods: This cross-sectional study included biologic-naive patients aged ≥18 years who had used nonbiologic systemic therapy 28–365 days prior to their registry enrollment between April 2015 and August 2022. A switch to biologic therapy was defined as the introduction of biologic treatment up to 45 days post-enrollment, in addition to or in place of the initial nonbiologic systemic therapy. Measures of patient-reported disease burden collected at enrollment were: the Dermatology Life Quality Index (DLQI); Work Productivity and Activity Impairment Index (WPAI); itch, skin pain, fatigue, and Patient Global Assessment (PGA), measured on visual analog scales (VAS); and the EuroQoL 5-Dimension, 3-Level (EQ-5D-3L) questionnaire. The association between each patient-reported disease burden measure and switching to biologic therapy was evaluated using multivariable logistic regression models, adjusting for age, sex, race, ethnicity, work status, body mass index, psoriasis duration, psoriatic arthritis status, disease severity, number of prior nonbiologic therapies used, and history of difficult-to-treat areas. A secondary analysis stratified each model by patients with PASI scores ≤2 or >2. Results: Of 848 patients included in the analysis, 323 (38.1%) switched to biologic treatment at enrollment. Significantly higher odds of switching were observed for patients reporting greater vs lesser burden on the DLQI (adjusted odds ratio [aOR] = 1.55; 95% CI, 1.08–2.23); VAS measures of itch (aOR = 2.14; 95% CI, 1.49–3.08), skin pain (aOR = 2.18; 95% CI, 1.45–3.29), fatigue (aOR = 1.66; 95% CI, 1.15–2.40), or PGA (aOR = 3.09; 95% CI, 1.94–4.91); or WPAI activities impairment (aOR = 2.51; 95% CI, 1.72–3.65). Numerically higher odds of switching were observed for greater vs lesser burden measured by EQ-5D-3L. In the secondary analysis, 52 of 330 patients with PASI scores ≤2 (15.8%) switched to biologic treatment. Among patients with PASI scores ≤2, those with greater vs lesser burden for VAS itch, skin pain, or PGA, or with impairment of their usual activities as measured by EQ-5D-3L had significantly higher odds of switching to biologic treatments. Conclusion: Data collected from real-world patients with plaque psoriasis suggest that, in addition to disease severity, patient-reported disease burden, such as itch and skin pain, may be an important driver of switching from a nonbiologic to biologic therapy, even among patients with a low degree of skin involvement. Sponsored by: CorEvitas.
{"title":"Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy","authors":"Sang Hee Park, Y. Zhong, A. Sima, V. Patel, J. Zhuo, C. Roberts-Toler, B. Becker, S. Hovland, B. Strober","doi":"10.25251/skin.7.supp.113","DOIUrl":"https://doi.org/10.25251/skin.7.supp.113","url":null,"abstract":"Introduction: Better understanding of the relationship between quality of life and treatment patterns in psoriasis may help guide therapeutic algorithms. This study evaluated the association between patient-reported disease burden and treatment switching from nonbiologic to biologic therapy in patients with plaque psoriasis enrolled in the CorEvitas Psoriasis Registry. \u0000Methods: This cross-sectional study included biologic-naive patients aged ≥18 years who had used nonbiologic systemic therapy 28–365 days prior to their registry enrollment between April 2015 and August 2022. A switch to biologic therapy was defined as the introduction of biologic treatment up to 45 days post-enrollment, in addition to or in place of the initial nonbiologic systemic therapy. Measures of patient-reported disease burden collected at enrollment were: the Dermatology Life Quality Index (DLQI); Work Productivity and Activity Impairment Index (WPAI); itch, skin pain, fatigue, and Patient Global Assessment (PGA), measured on visual analog scales (VAS); and the EuroQoL 5-Dimension, 3-Level (EQ-5D-3L) questionnaire. The association between each patient-reported disease burden measure and switching to biologic therapy was evaluated using multivariable logistic regression models, adjusting for age, sex, race, ethnicity, work status, body mass index, psoriasis duration, psoriatic arthritis status, disease severity, number of prior nonbiologic therapies used, and history of difficult-to-treat areas. A secondary analysis stratified each model by patients with PASI scores ≤2 or >2. \u0000Results: Of 848 patients included in the analysis, 323 (38.1%) switched to biologic treatment at enrollment. Significantly higher odds of switching were observed for patients reporting greater vs lesser burden on the DLQI (adjusted odds ratio [aOR] = 1.55; 95% CI, 1.08–2.23); VAS measures of itch (aOR = 2.14; 95% CI, 1.49–3.08), skin pain (aOR = 2.18; 95% CI, 1.45–3.29), fatigue (aOR = 1.66; 95% CI, 1.15–2.40), or PGA (aOR = 3.09; 95% CI, 1.94–4.91); or WPAI activities impairment (aOR = 2.51; 95% CI, 1.72–3.65). Numerically higher odds of switching were observed for greater vs lesser burden measured by EQ-5D-3L. In the secondary analysis, 52 of 330 patients with PASI scores ≤2 (15.8%) switched to biologic treatment. Among patients with PASI scores ≤2, those with greater vs lesser burden for VAS itch, skin pain, or PGA, or with impairment of their usual activities as measured by EQ-5D-3L had significantly higher odds of switching to biologic treatments. \u0000Conclusion: Data collected from real-world patients with plaque psoriasis suggest that, in addition to disease severity, patient-reported disease burden, such as itch and skin pain, may be an important driver of switching from a nonbiologic to biologic therapy, even among patients with a low degree of skin involvement. \u0000Sponsored by: CorEvitas.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45070272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.125
B. Strober, J. Zeichner, S. Desai, Michael C Cameron, J. Cather, Matthew J. Bruno, D. Rubenstein, A. Tallman, P. Brown
{"title":"Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial","authors":"B. Strober, J. Zeichner, S. Desai, Michael C Cameron, J. Cather, Matthew J. Bruno, D. Rubenstein, A. Tallman, P. Brown","doi":"10.25251/skin.7.supp.125","DOIUrl":"https://doi.org/10.25251/skin.7.supp.125","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42798343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.127
Michael Vecchiolla, N. Bhatia
{"title":"Patient Perspectives on use of a water-based Calcipotriene and Betamethasone Dipropionate Cream for the treatment of Plaque Psoriasis","authors":"Michael Vecchiolla, N. Bhatia","doi":"10.25251/skin.7.supp.127","DOIUrl":"https://doi.org/10.25251/skin.7.supp.127","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43919541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.126
L. Kircik, Mathew Zirwas, S. Kwatra, M. Lewitt, H. Glover, Tomas Chao, P. Brown, D. Rubenstein, A. Tallman
{"title":"Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis","authors":"L. Kircik, Mathew Zirwas, S. Kwatra, M. Lewitt, H. Glover, Tomas Chao, P. Brown, D. Rubenstein, A. Tallman","doi":"10.25251/skin.7.supp.126","DOIUrl":"https://doi.org/10.25251/skin.7.supp.126","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48540393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.140
A. Wollenberg, M. Cork, C. Flohr, A. Bewley, A. Blauvelt, C. Hong, S. Imafuku, M. Schuttelaar, E. Simpson, W. Soong, P. Amoudruz, Katja Wendicke Lophaven, A. Kurbasic, L. Soldbro, Natacha Strange Vest, A. Paller
{"title":"Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial","authors":"A. Wollenberg, M. Cork, C. Flohr, A. Bewley, A. Blauvelt, C. Hong, S. Imafuku, M. Schuttelaar, E. Simpson, W. Soong, P. Amoudruz, Katja Wendicke Lophaven, A. Kurbasic, L. Soldbro, Natacha Strange Vest, A. Paller","doi":"10.25251/skin.7.supp.140","DOIUrl":"https://doi.org/10.25251/skin.7.supp.140","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49194405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maansi Kulkarni, Sean Igelman, J. Trevino, C. Conner
The development of immune checkpoint inhibitors such as programmed cell-death receptor 1 (PD-1) antagonists has rapidly advanced chemotherapy within the last several decades. PD-1 targeted immunotherapy drugs like pembrolizumab, ipilimumab, nivolumab, and durvalumab have known associations with several immune-mediated dermatological reactions. We report a case in which an elderly male experienced segmental vitiligo after use of durvalumab therapy for small cell lung cancer. Distinct from non-segmental vitiligo, segmental vitiligo presents in a unilateral blaschkoid distribution and typically does not cross the midline. To our knowledge, checkpoint inhibitor-induced segmental vitiligo has yet to be documented.
{"title":"Linear Depigmented Macules and Patches in an Elderly Man","authors":"Maansi Kulkarni, Sean Igelman, J. Trevino, C. Conner","doi":"10.25251/skin.7.2.11","DOIUrl":"https://doi.org/10.25251/skin.7.2.11","url":null,"abstract":"The development of immune checkpoint inhibitors such as programmed cell-death receptor 1 (PD-1) antagonists has rapidly advanced chemotherapy within the last several decades. PD-1 targeted immunotherapy drugs like pembrolizumab, ipilimumab, nivolumab, and durvalumab have known associations with several immune-mediated dermatological reactions. We report a case in which an elderly male experienced segmental vitiligo after use of durvalumab therapy for small cell lung cancer. Distinct from non-segmental vitiligo, segmental vitiligo presents in a unilateral blaschkoid distribution and typically does not cross the midline. To our knowledge, checkpoint inhibitor-induced segmental vitiligo has yet to be documented.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48227569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.161
L. Kircik, T. Schlesinger, A. Armstrong, B. Berman, N. Bhatia, J. D. Del Rosso, M. Lebwohl, Vishal Patel, D. Rigel, Siva Narayanan, V. Koscielny, I. Kasujee
Introduction: Actinic Keratosis (AK) has been shown to negatively affect emotional functioning and skin-related quality of life of patients. Impact of tirbanibulin treatment on patients with AKs is not adequately understood. The primary objective of the study was to evaluate patient-reported outcomes in terms of AK symptoms, and impact of AKs on emotions and functioning, among AK patients treated with tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AK of the face or scalp who were newly initiated with tirbanibulin treatment in real-world community practices in the U.S, as part of usual care. Patients and clinicians completed surveys and clinical assessments at baseline, Week-8 (timeframe for main endpoints) and Week-24. Skindex-16, completed at baseline and Week-8, is a 16-item survey with 3 domains: symptoms (4 items), emotions (7 items) and functioning (5 items), with each domain score computed on a scale of 0 to 100 with higher score indicating severe impairment due to AKs. Changes from baseline in Skindex-16 scores were analyzed. Results: A total of 290 AK patients completed the study assessments at Week-8 (female: 31.38%; history of skin cancer: 61.72%; Fitzpatrick skin type: I: 7.59%, II: 71.38%, III: 18.62%, IV: 1.38%, V: 1.03%). Patient self-reported skin-texture was – dry: 39.66%, smooth: 47.59%, rough: 19.66%, bumpy: 18.62%, scaly: 35.17%, blistering/peeling: 6.55%. Baseline Skindex-16 domain scores were: symptoms: 22.30, emotions: 38.17, functioning: 14.41. At Week-8, a statistically significant (p<0.0001) decrease in scores from baseline was observed for all Skindex-16 domains, with Week-8 domain scores being: symptoms: 8.15, emotions: 13.49, functioning: 4.63. Conclusion: Patients with AKs who used once-daily tirbanibulin treatment for 5-days reported a significant reduction in AK burden, as indicated by the improvement in AK symptoms and emotional/functional impact, at Week-8.
{"title":"Impact of Actinic Keratosis (AK), as measured by patient-reported AK symptoms, and impact on emotions and functioning (using Skindex-16) among patients with AK administered tirbanibulin in real-world community practices across the U.S. (PROAK Study)","authors":"L. Kircik, T. Schlesinger, A. Armstrong, B. Berman, N. Bhatia, J. D. Del Rosso, M. Lebwohl, Vishal Patel, D. Rigel, Siva Narayanan, V. Koscielny, I. Kasujee","doi":"10.25251/skin.7.supp.161","DOIUrl":"https://doi.org/10.25251/skin.7.supp.161","url":null,"abstract":"Introduction: Actinic Keratosis (AK) has been shown to negatively affect emotional functioning and skin-related quality of life of patients. Impact of tirbanibulin treatment on patients with AKs is not adequately understood. The primary objective of the study was to evaluate patient-reported outcomes in terms of AK symptoms, and impact of AKs on emotions and functioning, among AK patients treated with tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AK of the face or scalp who were newly initiated with tirbanibulin treatment in real-world community practices in the U.S, as part of usual care. Patients and clinicians completed surveys and clinical assessments at baseline, Week-8 (timeframe for main endpoints) and Week-24. Skindex-16, completed at baseline and Week-8, is a 16-item survey with 3 domains: symptoms (4 items), emotions (7 items) and functioning (5 items), with each domain score computed on a scale of 0 to 100 with higher score indicating severe impairment due to AKs. Changes from baseline in Skindex-16 scores were analyzed. Results: A total of 290 AK patients completed the study assessments at Week-8 (female: 31.38%; history of skin cancer: 61.72%; Fitzpatrick skin type: I: 7.59%, II: 71.38%, III: 18.62%, IV: 1.38%, V: 1.03%). Patient self-reported skin-texture was – dry: 39.66%, smooth: 47.59%, rough: 19.66%, bumpy: 18.62%, scaly: 35.17%, blistering/peeling: 6.55%. Baseline Skindex-16 domain scores were: symptoms: 22.30, emotions: 38.17, functioning: 14.41. At Week-8, a statistically significant (p<0.0001) decrease in scores from baseline was observed for all Skindex-16 domains, with Week-8 domain scores being: symptoms: 8.15, emotions: 13.49, functioning: 4.63. Conclusion: Patients with AKs who used once-daily tirbanibulin treatment for 5-days reported a significant reduction in AK burden, as indicated by the improvement in AK symptoms and emotional/functional impact, at Week-8.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44641807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.162
T. Schlesinger, L. Kircik, A. Armstrong, B. Berman, N. Bhatia, J. D. Del Rosso, M. Lebwohl, Vishal Patel, D. Rigel, Siva Narayanan, V. Koscielny, I. Kasujee
Introduction: Actinic Keratosis (AK) are epidermal lesions with potential to progress to squamous cell carcinomas if left untreated. AKs have also been shown to negatively affect emotional functioning and skin-related quality of life of patients. The primary objective of the analysis was to evaluate IGA success at Week-8, and clinician-reported likelihood to consider tirbanibulin again for future treatments, among patients with AKs administered tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AKs on the face or scalp who were newly initiated with tirbanibulin treatment in real-world community practices in the U.S, as part of usual care. Patients and clinicians completed surveys and clinical assessments at baseline, Week-8 (timeframe for main endpoints) and Week-24. Clinicians assessed AK responses using an IGA on a five-point adjectival response scale of 0 (completely cleared), 1 (partially cleared), 2 (moderately cleared), 3 (minimally cleared) and 4 (not cleared). IGA success was defined as achieving an IGA score of 0 or 1 at Week-8. Clinicians also reported their likelihood to reuse tirbanibulin treatment for their patients, as a surrogate measure of satisfaction with the treatment. Results: A total of 290 AK patients completed the study assessments at Week-8 (female: 31.38%; history of skin cancer: 61.72%; Fitzpatrick skin type: I: 7.59%, II: 71.38%, III: 18.62%, IV: 1.38%, V: 1.03%). At Week-8, proportion of patients with completely/partially cleared AK (Approximately 75-100% clearance of AK lesions in the treated area, IGA 1/0) was 73.79%; moderately cleared (IGA 2) was 17.24%, and minimally cleared/not cleared (IGA 3/4) was 8.97%. Correspondingly, IGA success in this cohort of patients treated with tirbanibulin was 73.79%. Proportion of patients for whom clinicians noted that they would ‘somewhat or very likely’ consider tirbanibulin treatment again, if need arises, was 85.17%, with 7.59% reporting a neutral response, and 7.24% reporting ‘somewhat or very unlikely’ to consider treatment with tirbanibulin again. Conclusion: Overwhelming majority of patients with AK using tirbanibulin experienced IGA success at Week-8, and an overwhelming majority of clinicians reported their desire to consider tirbanibulin again to treat AK lesions for their patients.
{"title":"Investigator Global assessment (IGA) of Actinic Keratosis (AK) among patients administered tirbanibulin in real-world community practices across the U.S., and clinician likelihood to consider tirbanibulin again for future AK treatments (PROAK Study)","authors":"T. Schlesinger, L. Kircik, A. Armstrong, B. Berman, N. Bhatia, J. D. Del Rosso, M. Lebwohl, Vishal Patel, D. Rigel, Siva Narayanan, V. Koscielny, I. Kasujee","doi":"10.25251/skin.7.supp.162","DOIUrl":"https://doi.org/10.25251/skin.7.supp.162","url":null,"abstract":"Introduction: Actinic Keratosis (AK) are epidermal lesions with potential to progress to squamous cell carcinomas if left untreated. AKs have also been shown to negatively affect emotional functioning and skin-related quality of life of patients. The primary objective of the analysis was to evaluate IGA success at Week-8, and clinician-reported likelihood to consider tirbanibulin again for future treatments, among patients with AKs administered tirbanibulin in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROAK) was conducted among adult patients with AKs on the face or scalp who were newly initiated with tirbanibulin treatment in real-world community practices in the U.S, as part of usual care. Patients and clinicians completed surveys and clinical assessments at baseline, Week-8 (timeframe for main endpoints) and Week-24. Clinicians assessed AK responses using an IGA on a five-point adjectival response scale of 0 (completely cleared), 1 (partially cleared), 2 (moderately cleared), 3 (minimally cleared) and 4 (not cleared). IGA success was defined as achieving an IGA score of 0 or 1 at Week-8. Clinicians also reported their likelihood to reuse tirbanibulin treatment for their patients, as a surrogate measure of satisfaction with the treatment. Results: A total of 290 AK patients completed the study assessments at Week-8 (female: 31.38%; history of skin cancer: 61.72%; Fitzpatrick skin type: I: 7.59%, II: 71.38%, III: 18.62%, IV: 1.38%, V: 1.03%). At Week-8, proportion of patients with completely/partially cleared AK (Approximately 75-100% clearance of AK lesions in the treated area, IGA 1/0) was 73.79%; moderately cleared (IGA 2) was 17.24%, and minimally cleared/not cleared (IGA 3/4) was 8.97%. Correspondingly, IGA success in this cohort of patients treated with tirbanibulin was 73.79%. Proportion of patients for whom clinicians noted that they would ‘somewhat or very likely’ consider tirbanibulin treatment again, if need arises, was 85.17%, with 7.59% reporting a neutral response, and 7.24% reporting ‘somewhat or very unlikely’ to consider treatment with tirbanibulin again. Conclusion: Overwhelming majority of patients with AK using tirbanibulin experienced IGA success at Week-8, and an overwhelming majority of clinicians reported their desire to consider tirbanibulin again to treat AK lesions for their patients.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46782663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.200
Elaine S. Siegfried, Samantha Ong, J. Andres, C. Crosby, Melissa Olivadoti
{"title":"Quality of Information on Molluscum Contagiosum Consumer Websites","authors":"Elaine S. Siegfried, Samantha Ong, J. Andres, C. Crosby, Melissa Olivadoti","doi":"10.25251/skin.7.supp.200","DOIUrl":"https://doi.org/10.25251/skin.7.supp.200","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42267521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13DOI: 10.25251/skin.7.supp.130
L. Green, J. Bagel, G. Han, A. Jacobson, Martha Sikes
{"title":"Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis: Epidermal Permeation, Efficacy, and Safety","authors":"L. Green, J. Bagel, G. Han, A. Jacobson, Martha Sikes","doi":"10.25251/skin.7.supp.130","DOIUrl":"https://doi.org/10.25251/skin.7.supp.130","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48793328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：